Back to Search
OWEN O'CONNOR, MD
MD
Medical Oncology Physician
NPI: 1245201052IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
203055(NY)
Education
RUTGERS NEW JERSEY MEDICAL SCHOOL
Class of 1994
Research & Publications (20)
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
PMID 19652067·J Clin Oncol·2009
3-trial
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
PMID 19220284·Br J Haematol·2009
3-trial
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
PMID 18821434·Leuk Lymphoma·2008
6-review
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
PMID 18691173·Br J Haematol·2008
3-trial
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
PMID 16675587·Clin Cancer Res·2006
7-preclinical
New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
PMID 17027659·Semin Hematol·2006
6-review
Pralatrexate: an emerging new agent with activity in T-cell lymphomas.
PMID 16988580·Curr Opin Oncol·2006
6-review
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
PMID 16330674·J Clin Oncol·2006
8-other
Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
PMID 16354324·Clin Lymphoma Myeloma·2005
6-review
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
PMID 15613699·J Clin Oncol·2005
3-trial
Targeting histones and proteasomes: new strategies for the treatment of lymphoma.
PMID 16155030·J Clin Oncol·2005
4-observational
The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.
PMID 15233904·Curr Treat Options Oncol·2004
4-observational
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
PMID 17910632·Br J Haematol·2007
3-trial
Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways.
PMID 18024640·Hematology Am Soc Hematol Educ Program·2007
8-other
Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia.
PMID 19408055·Ann Surg Oncol·2009
5-case
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
PMID 19474785·Clin Pharmacol Ther·2009
8-other
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
PMID 19604235·Br J Haematol·2009
7-preclinical
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
PMID 19624539·Br J Haematol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (646) 227-3813
Quick Facts
- NPI
- 1245201052
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile